+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

mRNA Therapeutics and Vaccines Market, 2020-2030

  • ID: 5306192
  • Report
  • January 2021
  • Region: Global
  • 253 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 10x Genomics
  • Cancer Research Institute
  • Fund+
  • Life Sciences Partners
  • Platinum Asset Management
  • Steam Athena Capital

Overview

Medical researchers first began evaluating mRNA as a therapeutic modality in the 1990s. The clinical use of mRNA is presently being evaluated in both therapeutic (protein replacement therapies, and as an alternative to classical gene therapies) and preventive (mRNA vaccines) roles. There are over 65 mRNA therapeutics and more than 85 vaccines currently in the development pipeline. As a biomolecule, mRNA is well tolerated in vivo, and (depending on the encoded protein) is capable of inducing humoral and cell-mediated immune responses. Moreover, using this approach, researchers have demonstrated that it is possible to deliver adequate amounts of tumor antigens (bearing patient-specific molecular signatures), and provide the necessary costimulatory signals to mount an effective anticancer immune response. As indicated earlier, mRNA-based interventions are also being evaluated as protein replacement therapies and alternatives to classical gene therapies; however, research on the aforementioned modalities is still in its infancy, with several potential leads in the preclinical stages. Such therapies are predominantly being developed for treating rare disorders. On the other hand, using mRNA, it is possible to develop both personalized (for various cancer) and general-use vaccines (for infectious diseases). Interestingly, mRNA vaccines have shorter development and manufacturing timelines, compared to their traditional counterparts. In fact, Pfizer and BioNtech’s recently approved vaccine (BNT-162) and Moderna’s late phase candidate (mRNA-1273) against the novel coronavirus strain, are both mRNA-based preventive solutions.

Despite the potential benefits, there are, however, several challenges that limit the use of mRNA as a therapeutic. One of the major concerns is related to the short cytoplasmic half-life of the molecule, which compromises its efficacy as a therapeutic / vaccine. Other known setbacks of using mRNA as a therapy include its large size and inherent antigenicity, which complicate therapy administration and immune tolerance, respectively. Over the years, manipulation of the chemical structure of mRNA has enabled medical researchers and therapy developers to address some of the aforementioned challenges. Similarly, with regards to therapy delivery, lipoplexes and lipid-based nanoparticles are now preferred vehicles (among other contemporary nucleic acid delivery methods) for the targeted, intracellular delivery of therapeutic mRNA. However, companies (mostly startups and small firms) engaged in this field still claim to be in pursuit of better drug delivery strategies. In the last five years alone, close to USD 8 billion has been invested into companies that are engaged in developing mRNA-based therapeutics and vaccines; a significant proportion of the capital has come from public sector investors / state-backed institutes. Further, over the last few years, there has been noticeable consolidation, with stakeholders entering into strategic partnerships to support ongoing R&D initiatives. In the foreseen future, as more mRNA-based therapeutic / vaccine leads demonstrate proof-of-concept, enter into clinical testing and are eventually marketed, the opportunity for stakeholders engaged in this niche industry segment is anticipated to witness substantial growth.

Scope of the Report

The “mRNA Therapeutics and Vaccines Market, 2020-2030” report features an extensive study of the current market landscape and future potential of the players engaged in the development of mRNA-based therapeutics and vaccines for the treatment of a variety of disease conditions. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. 

Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of mRNA therapeutics and vaccines, along with information on type of product candidate, phase of development, type of development program, type of delivery vehicle, target disease indication, target therapeutic area and route of administration. It also includes details related to year of establishment, company size (in terms of number of employees) and location of headquarters of the drug developers. Further, it presents an elaborate analysis of the contemporary trends, presented using two schematic representations, including [A] logo landscape, highlighting the distribution of drug developers based on company size and location of their headquarters, and [B] grid analysis, presenting the distribution of drugs based on target disease indication, type of development program and type of candidate. It also provides a detailed analysis of key therapeutic areas, such as oncological disorders and infectious diseases, for which mRNA-based therapeutics and vaccines are being developed.
  • A competitiveness analysis of key players engaged in this domain. The analysis is presented in the form of spider web representations, which take into consideration several important parameters, such as number of early stage candidates, number of late stage candidates, number of deals signed, amount raised through funding, company size (in terms of number of employees) and years of experience in the industry. 
  • Detailed profiles of drug candidates that are in advanced stages of development. Each profile features an overview of the drug and respective developer, details related to type of candidate, route of administration, phase of development, target disease indication and therapeutic area, mechanism of action, technology used, and recent developments (including information of partnerships, clinical trials and results and special review designations awarded).
  • An analysis of the completed, ongoing and planned clinical studies for mRNA therapeutics and vaccines. The trials considered in the analysis were analyzed on the basis of various relevant parameters, such as trial registration year, trial recruitment status, number of patients enrolled, study design, target patient segment, trial focus area, target therapeutic area, geographical location of trials and leading organizations.
  • An in-depth analysis of the various patents that have been filed / granted related to mRNA delivery technologies / methods, since 2017. The analysis also highlights the key parameters associated with the patents, including information on patent application year, patent publication year, geographical location / patent jurisdiction, IPCR symbols, emerging focus areas and leading players. In addition, it includes detailed patent benchmarking analysis based on leading players. Further, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • An analysis of the partnerships that have been inked by stakeholders engaged in the development of mRNA-based therapeutics and vaccines, during the period 2013-2020, including research agreements, research and development agreements, contract manufacturing agreements, licensing agreements, and other relevant types of deals. 
  • An analysis of the investments made, including award / grant, seed financing, venture capital financing, debt financing and others, in companies that are engaged in the development of mRNA-based therapeutics and vaccines
  • A discussion on the affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution, under an elaborate SWOT framework. It also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.  

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the mRNA therapeutics and vaccines market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] key therapeutic areas (infectious diseases and oncological disorders), [B] route of administration (intravenous and intramuscular) and [D] key geographical regions (North America, Europe, Asia Pacific, MENA and LATAM regions). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Key Questions Answered

  • Who are the leading players engaged in the development of mRNA therapeutics and vaccines?
  • Which key clinical conditions can be treated by mRNA drugs?
  • What are the investment trends in this industry?
  • Which partnership models are commonly adopted by stakeholders engaged in this domain?
  • Which regions have emerged as the key hubs for conducting clinical studies focused on mRNA drugs?
  • How has the intellectual property landscape in this market evolved over the years?
  • Which factors are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 10x Genomics
  • Cancer Research Institute
  • Fund+
  • Life Sciences Partners
  • Platinum Asset Management
  • Steam Athena Capital

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. mRNA Therapeutics
3.2.1. Advantages of mRNA Therapeutics
3.2.2. Applications of mRNA Therapeutics
3.3. mRNA Vaccines
3.3.1. Advantages of mRNA Vaccines
3.3.2. Applications of mRNA Vaccines
3.4. Delivery Routes for mRNA Therapeutics and Vaccines
3.5. mRNA Delivery Strategies
3.6. Challenges Associated with mRNA Therapeutics and Vaccines

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. mRNA Therapeutics and Vaccines: Development Pipeline
4.2.1. Analysis by Type of Product Candidate
4.2.2. Analysis by Phase of Development
4.3.3. Analysis by Type of Development Program
4.2.4. Analysis by Type of Delivery Vehicle
4.2.5. Analysis by Disease Indication
4.2.6. Analysis by Target Therapeutic Area
4.2.7. Analysis by Route of Administration
4.2.8. Key mRNA-based Technology Platforms
4.2.9 Key Players
4.2.10 Clinical Stage Candidates: Sales Rights
4.3. mRNA Therapeutics and Vaccines: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.4 Logo Landscape: Analysis by Company Size and Location of Headquarters
4.5 Grid Analysis by Disease Indication, Type of Program and Type of Candidate

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Parameters and Methodology
5.3. Spider Web Analysis

6. DRUG PROFILES
6.1. Chapter Overview
6.2. mRNA-1273 (Moderna Therapeutics)
6.3. BNT162 (BioNTech)
6.4. AZD8601 (Moderna Therapeutics / AstraZeneca)
6.5. BNT122 (BioNTech)
6.6. COVID-19 (CureVac)
6.7. mRNA-1647 (Moderna Therapeutics)
6.8. mRNA-4157 (Moderna Therapeutics)
6.9. mRNA-2416 (Moderna Therapeutics)
6.10. mRNA-3927 (Moderna Therapeutics)
6.11. MRT5005 (Translate Bio)

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. mRNA Therapeutics and Vaccines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Registration Year and Trial Recruitment Status
7.3.3. Analysis by Trial Registration Year and Number of Patients Enrolled
7.3.4. Analysis by Study Design
7.3.5. Analysis by Patient Segment
7.3.6. Analysis by Trial Focus Area
7.3.7. Analysis by Therapeutic Area
7.3.8. Geographical Analysis by Number of Clinical Trials
7.3.9. Geographical Analysis by Trial Registration Year and Enrolled Patient Population
7.3.10. Leading Organizations: Analysis by Number of Registered Trials

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. mRNA Technologies / Methods: Patent Analysis
8.3.1. Analysis by Application Year
8.3.2. Analysis by Publication Year
8.3.3. Analysis by Geographical Location
8.3.4. Analysis by IPCR Symbols
8.3.5. Analysis by Emerging Focus Areas
8.3.6. Leading Players: Analysis by Number of Patents
8.3.7. mRNA Technologies / Methods: Patent Benchmarking Analysis
8.3.7.1 Analysis by Key Patent Characteristics
8.3.8 mRNA Technologies / Methods: Patent Valuation Analysis

9. RECENT PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnership Models
9.3. mRNA Therapeutics and Vaccines: Recent Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Therapeutic Area
9.3.4. Most Active Players: Analysis by Number of Partnerships
9.3.5. Regional Analysis

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. mRNA Therapeutics and Vaccines: Funding and Investment Analysis
10.3.1. Analysis by Cumulative Funding Instances, 2010-2020
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Year and Type of Funding
10.3.5. Regional Analysis by Amount Invested
10.3.6. Most Active Players: Analysis by Number of Funding Instances and Amount Raised
10.3.7. Key Investors: Analysis by Number of Funding Instances

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Scope and Limitations
11.3. Key Assumptions and Forecast Methodology
11.4. Overall mRNA Therapeutics and Vaccines Market, 2020-2030
11.4.1. mRNA Therapeutics and Vaccines Market: Analysis by Key Therapeutic Areas
11.4.2. mRNA Therapeutics and Vaccines Market: Analysis by Route of Administration
11.4.3. mRNA Therapeutics and Vaccines Market: Analysis by Geography
11.5. mRNA Therapeutics and Vaccines Market: Product-wise Sales Forecasts
11.5.1. mRNA-1273
11.5.1.1. Target Patient Population
11.5.1.2. Sales Forecast
11.5.2. BNT-162
11.5.2.1. Target Patient Population
11.5.2.2. Sales Forecast
11.5.3. AZD8601
11.5.3.1. Target Patient Population
11.5.3.2. Sales Forecast
11.5.4. COVID-19
11.5.4.1. Target Patient Population
11.5.4.2. Sales Forecast
11.5.5. mRNA-1647
11.5.5.1. Target Patient Population
11.5.5.2. Sales Forecast
11.5.6. mRNA-4157
11.5.6.1. Target Patient Population
11.5.6.2. Sales Forecast
11.5.7. ARCT-021
11.5.7.1. Target Patient Population
11.5.7.2. Sales Forecast

12. SWOT ANALYSIS
12.1. Chapter Overview
12.2 Comparison of SWOT Factors
12.2.1 Concluding Remarks

13. CONCLUSION
13.1. Chapter Overview
13.2. Key Takeaways

14. mRNA THERAPEUTICS AND VACCINES: EXPERT INSIGHTS
14.1. Chapter Overview
14.2. Industry Experts
14.2.1. Stéphane Bancel, President / Founding Chief Executive Officer (Moderna)
14.2.2. Ugur Sahin, Chief Executive Officer / Co-Founder (BioNTech)
14.2.3. Patrick Baumhof, Vice President Formulation and Delivery CureVac
14.2.4. Anna Collén, Project Leader (AstraZeneca)

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Note: Product cover images may vary from those shown
  • Arcturus Therapeutics
  • Shanghai Bendao Gene Technology
  • BIOCAD
  • BioNTech
  • CanSinoBIO
  • Chimeron Bio
  • CureVac
  • Daiichi Sankyo
  • Elixirgen Therapeutics
  • eTheRNA
  • ethris
  • Gennova Biopharmaceuticals
  • GreenLight Biosciences
  • HDT Bio
  • Kernal Biologics
  • Mercurna
  • Moderna
  • Pantherna Therapeutics
  • Providence Therapeutics
  • ReCode Therapeutics
  • Rejuvenation Technologies
  • RNACure Biopharma
  • RNAimmune
  • Stemirna Therapeutics
  • Tiba Biotech
  • Translate Bio
  • Versameb
  • Walvax Biotechnology
  • Ziphius Vaccines
  • Neurimmune
  • AstraZeneca
  • University of Münster
  • 20Med Therapeutics
  • Centro Nacional de Investigaciones Cardiovasculares (CNIC)
  • cmRNAbone
  • Alexion Pharmaceuticals
  • Karolinska Institutet
  • Merck
  • PPD
  • Vertex Pharmaceuticals
  • Lonza
  • Catalent
  • LABORATORIOS FARMACEUTICOS ROVI
  • Amazon Web Services
  • Chiesi Farmaceutici 
  • Institut Pasteur
  • United Kingdom Government
  • Takeda Pharmaceuticals
  • Qatar Government
  • Frame Therapeutics
  • Mymetics
  • Image Analysis Group (IAG)
  • Recipharm
  • Johnson & Johnson Innovation
  • Alcobra Pharmaceuticals
  • Ultragenyx Pharmaceutical
  • Janssen Pharmaceuticals
  • Precision NanoSystems
  • Duke-NUS Medical School
  • European Union
  • GlaxoSmithKline
  • Coalition for Epidemic Preparedness Innovations (CEPI)
  • Genmab 
  • Yale University
  • Harvard Medical School
  • Eli Lilly
  • Bill & Melinda Gates Foundation
  • Boehringer Ingelheim
  • Cancer Research Institute
  • Acuitas Therapeutics
  • Sanofi 
  • Albany Molecular Research
  • Shire
  • Shanghai East Hospital
  • National Institute on Aging (NIA)
  • Astellas Innovation Management
  • PROVIREX Genome Editing Therapies
  • Helmholtz-Zentrum Geesthacht
  • Fudan University
  • Körber
  • Beijing Institute of Biotechnology
  • Genentech
  • Bayer
  • Pfizer
  • Genevant Sciences
  • University of Pennsylvania
  • Regeneron Pharmaceuticals
  • Neon Therapeutics
  • Shanghai Fosun Pharmaceutical
  • Karolinska University Hospital
  • MedImmune
  • Shanghai Jiao Tong University
  • AO Foundation
  • Paracelsus Medical University
  • Ludwig Institute for Cancer Research
  • dievini Hopp BioTech Holding
  • Flagship Pioneering
  • Life Sciences Partners
  • Maryland Stem Cell Research Fund
  • Morningside Group
  • State Development & Investment
  • University of Tokyo Edge Capital
  • Abu Dhabi Investment Authority (ADIA)
  • Atlas Venture
  • Baillie Gifford
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Defense Advanced Research Projects Agency (DARPA)
  • European Investment Bank
  • Fall Line Capital
  • S2G Ventures
  • Flanders Innovation & Entrepreneurship 
  • Flu Lab
  • High-Tech Gründerfonds (HTGF)
  • Lapam Capital
  • Lilly Asia Ventures
  • MassChallenge
  • MRL Ventures Fund
  • Viking Global Investors
  • OrbiMed Advisors
  • Redmile Group
  • Qiming Venture Partners
  • Kreditanstalt für Wiederaufbau (KfW)
  • Qatar Investment Authority (QIA)
  • Temasek Holdings
  • Baupost Group
  • Y Combinator
  • Terra Magnum Capital Partners
  • Venture Challenge
  • Zoic Capital 
  • Bpifrance
  • UNIIQ
  • BB Biotech
  • Boston Biotech Ventures
  • Chartwave
  • Colt Ventures
  • Baird Capital
  • Monsanto
  • Boehringer Ingelheim Venture Fund
  • Coppel Family
  • Cormorant Asset Management
  • Fund+
  • Invus
  • Macro Capital
  • MPM Capital
  • RA Capital Management
  • Spinnotec
  • Continental Grain Company (CGC)
  • Julius Baer
  • Redmile Group
  • Omega Funds
  • Wellington Management
  • SIGMA Group
  • ELMA Investments
  • Fidelity Management
  • Jiuyo Capital
  • Blue I/O
  • Boehringer Ingelheim Venture Fund
  • Fang Fund Partners
  • Hunt Technology Ventures
  • MiraeAsset Financial Group
  • Malaysian Life Sciences Capital Fund
  • Rock Springs Capital
  • Alexandria Venture Investments
  • Brookside Capital
  • Grand Decade
  • Osage University Partners
  • Longmen capital
  • Platinum Asset Management
  • Syngenta Ventures
  • Tao Capital Partners
  • Struengmann Family Office
  • Healthcare Holdings
  • Jebsen Capital
  • Leerink Partners
  • Pictet Group
  • Steam Athena Capital
  • Viking Global Investors
  • Lewis & Clark AgriFood
  • BVCF Management
  • ArrowMark Partners
  • BNP Paribas Fortis Private Equity
  • Lupa Systems
  • Novalis LifeSciences
  • Yijing Capital
  • Immatics
  • Roche
  • Novartis
  • Regeneron Pharmaceuticals
  • Seminis
  • Ionis Pharmaceuticals
  • 10x Genomics
  • National Institute of Health
  • Dana-Farber Cancer Institute
  • Broad Institute
  • Stanford University
  • University of Texas
  • Harvard University
  • Massachusetts Institute of Technology
  • University of California
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll